OR WAIT null SECS
- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Rheumatology Network's Top 5: June 11, 2021
Lana Dykes is the Editor of Rheumatology Network. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. She enjoys cooking, yoga, and drawing.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 11, 2021.
The 2021 Treatment Guidelines for Rheumatoid Arthritis
The American College of Rheumatology has updated its treatment guidelines for rheumatoid arthritis. The guideline includes 44 treatment recommendations, 7 of which are now strongly recommended.
Click the image to view the story.
Benjamin Nowell, PhD: Mindfulness Program for Patients With Rheumatic Disease
Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.
Click the image to view the story.
Swollen Joint Count Questioned in Moderate, Oligoarticular Psoriatic Arthritis
In addition to swollen joint count, joint location and functional impairment should also be considered when describing psoriatic arthritis as moderate.
Click the image to view the story.
Eugen Feist, MD: Olokizumab Emerges as Promising Therapy for Rheumatoid Arthritis
Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.
Click the image to view the story.
Alyssa Johnsen, MD, PhD: Guselkumab Improves Joint Symptoms and Skin Clearance in Psoriatic Arthritis
Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.
Click the image to view the story.
Related Content:
